EUVIMEDEUVIMED entdecken
Crossref

In Brief: A Second Indication for Tucatinib (Tukysa)

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1670g ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Oxazoles, Pyridines.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The oral kinase inhibitor tucatinib (Tukysa – Seagen) has received accelerated approval from the FDA for use in combination with trastuzumab (Herceptin) for treatment of adults with RAS wild-type human epidermal growth factor receptor 2 (HER2)-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy regimens. Tucatinib was approved in 2020 for use in combination with trastuzumab and capecitabine (Xeloda, and generics) for treatment of adults with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who received at least one prior anti-HER2-based regimen for metastatic disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OxazolesPyridinesHumansQuinazolines

Stichwörter der Autor:innen

HerceptinTukysaXelodaadverse effectscancercapecitabinecolorectaldosagedrug interactionsefficacyfluoropyrimidineirinotecanlactationoxaliplatinpregnancy

Substanzen

tucatinibOxazolesPyridinesQuinazolines

Zitieren

APA

(2023). In Brief: A Second Indication for Tucatinib (Tukysa). The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1670g

Vancouver

In Brief: A Second Indication for Tucatinib (Tukysa). The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1670g

BibTeX
@article{euvimed2023,
  title = {In Brief: A Second Indication for Tucatinib (Tukysa)},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1670g}
}
Kostenlos starten →